PopVax dosed the first participants in a Phase 1 trial of PVX-001, a broadly protective COVID-19 vaccine candidate, in Melbourne on 31 August 2026. The trial will enroll 36 healthy adults to test safety and immune response breadth; as of 6 October, 14 participants had been dosed with no serious adverse events reported. The vaccine uses PopVax's own protein design, mRNA-VLP architecture, and fridge-stable lipid nanoparticle delivery, built in-house over 4.5 years, and will be open-sourced once the trial concludes.
chronicles.popvax.com
· 2026-10-10
The CDC has not finalized procurement decisions allowing states to order this season's COVID-19 vaccines through the Vaccines for Children program, which covers roughly 52 percent of US children who are uninsured, underinsured, Medicaid-eligible, or Indigenous. The delay also affects at least 11 states and one US territory that use VFC contracts to buy vaccines universally for all children regardless of insurance status. HHS, led by Robert F. Kennedy Jr., confirmed the procurement decisions remain unfinished but did not explain the reason for the delay.
arstechnica.com
· 2026-09-23
Despite chaos at the CDC's vaccine advisory panel and RFK Jr.'s anti-vaccine actions as health secretary, updated flu and COVID-19 vaccines have been FDA-approved and are already shipping to pharmacies for the fall season. Major insurers have agreed to keep covering previously recommended vaccines at no cost through at least 2027, and state health officials expect a mostly normal rollout.
arstechnica.com
· 2026-09-09
GoKawiil